Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes 1 , 2 . The clinical presentation of patients with different subtypes is often …

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several previously …

B cells are a major component of the tumour microenvironment, where they are predominantly
associated with tertiary lymphoid structures (TLS). In germinal centres within mature TLS, …

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic
option to a robust clinical reality. Many immunotherapeutic regimens are now approved …

The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor sites …

We introduce the Microenvironment Cell Populations-counter (MCP-counter) method, which
allows the robust quantification of the absolute abundance of eight immune and two stromal …

Head and neck cancers positive for human papillomavirus (HPV) have a more favorable
clinical outcome than HPV-negative cancers, but it is unknown why this is the case. We …

Motivation The composition and density of immune cells in the tumor microenvironment (TME)
profoundly influence tumor progression and success of anti-cancer therapies. Flow …

Purpose: CD4 + T cells play a central role in initiating and maintaining anticancer immune
responses. However, regulatory CD4 + CD25 + T cells which express Foxp3 have also been …

Only a minority of patients derive long-term clinical benefit from anti-programmed cell death
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies…